Self-Assembled Glycopeptide as a Biocompatible mRNA Vaccine Platform Elicits Robust Antitumor Immunity

Area of Science:

• Biotechnology
• Vaccinology
• Nanomedicine

Background:

• Messenger RNA (mRNA) vaccines have gained prominence, particularly since the COVID-19 pandemic.
• Effective and safe delivery vectors are crucial for mRNA vaccine efficacy, but current options are limited.
• Self-assembled glycopeptides (SAPs) offer a promising platform for developing novel drug delivery systems.

Purpose of the Study:

• To develop a novel mRNA delivery vector, Man-MPm, utilizing self-assembled glycopeptides (SAPs).
• To engineer Man-MPm for enhanced lymph node targeting and STING pathway activation.
• To evaluate the safety and efficacy of Man-MPm-based mRNA vaccines in preclinical tumor models.

Main Methods:

• Development of Man-MPm by coupling mannose and manganese ions to SAPs.
• Assessment of Man-MPm biosafety across various administration routes.
• Evaluation of antigen-specific immune responses and antitumor effects in melanoma and colon cancer mouse models.

Main Results:

• Man-MPm demonstrated high biosafety and facilitated robust, lymph node-localized, antigen-specific immune responses.
• The Man-MPm-based mRNA vaccine significantly suppressed tumor growth in melanoma and colon cancer models.
• Treatment with Man-MPm extended survival periods in preclinical cancer models.

Conclusions:

• Man-MPm effectively addresses safety and delivery challenges for mRNA vaccines.
• The combination of lymph node targeting and STING pathway activation enhances vaccine efficacy.
• Man-MPm shows significant potential for the development of advanced mRNA tumor vaccines.